A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy.

ABSTRACT:

Background

Only a fraction of patients with esophageal squamous cell carcinoma (ESCC) show tumor responses to anti-programmed cell death protein 1 (PD-1) therapy. The predictive value of single biomarkers for prognosis is limited, and a more comprehensive approach that incorporates multiple factors may improve the prognostic prediction. Here, we conducted a retrospective study to develop a combined immune prognostic index (CIPI) for predicting clinical outcomes of ESCC patients treated with anti-PD-1 therapy.

Design and methods

We performed a pooled analysis of two multicenter clinical trials comparing immunotherapy versus chemotherapy as second-line treatment in ESCC patients. The discovery cohort comprised patients who received anti-PD-1 inhibitors (N = 322)

SUBMITTER: Ji S 

PROVIDER: S-EPMC10272641 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature